β-conglycinin effectively prevented high-sucrose induced fatty liver through suppression of SREBP-1c and carbohydrate response element-binding protein mRNA [59], and lowered hepatic triglycerides, serum insulin and leptin concentrations and prevented high-fat induced fatty liver via suppression of liver PPARγ2 and/or SREBP-1c protein in mice [59, 70]. The gene discussed is PPARG; the disease is Hepatic steatosis.